Chronic semaglutide treatment reduces weight without impairing taste function in obese mice
Background
Despite the high efficacy of GLP-1 receptor (GLP-1R) agonists like semaglutide for obesity treatment, the precise mechanisms behind their appetite-reducing effects remain partially understood. Taste plays a crucial role in regulating food intake, and clinical studies investigating whether GLP-1R agonists alter taste function have yielded conflicting results. Understanding this interaction is vital, as taste aversion could impact patient adherence and quality of life, while taste enhancement might reveal novel pathways for appetite modulation.
Study Design
Researchers systematically tested the effects of chronic semaglutide on taste responsivity in diet-induced obese mice. Mice were assessed using brief-access gustometer tests to evaluate responses to sweet, bitter, sour, salty, and fatty tastants. Psychophysical analysis involved a broad range of sucrose concentrations to determine sweet taste sensitivity. Additionally, the study examined the abundance of taste receptor cell subtypes in the circumvallate papilla and the expression of genes involved in taste receptor signaling and neurotransmission. Vehicle-treated mice served as the control arm.
Results
Chronic semaglutide treatment produced robust weight loss in diet-induced obese mice. Crucially, it did not alter lick rates for any tested tastant (sweet, bitter, sour, salty, fatty), indicating intact taste-driven orosensory evaluation across modalities. Psychophysical analysis using various sucrose concentrations revealed similar concentration-response functions and comparable EC50 values between vehicle- and semaglutide-treated mice, demonstrating unchanged sweet taste sensitivity. However, semaglutide modestly increased total licking and trial initiation for sucrose, suggesting enhanced behavioral engagement rather than altered taste perception. Consistent with these behavioral findings, semaglutide did not affect the abundance of taste receptor cell subtypes in the circumvallate papilla or the expression of genes involved in taste receptor signaling and neurotransmission.
Key Findings
- Chronic semaglutide treatment led to robust weight loss in diet-induced obese mice.
- Semaglutide did not alter lick rates for sweet, bitter, sour, salty, or fatty tastants.
- Sweet taste sensitivity, including
EC50values, remained unchanged with semaglutide treatment. - Semaglutide modestly increased total licking and trial initiation for sucrose, suggesting enhanced behavioral engagement.
- Taste receptor cell subtype abundance and gene expression related to taste signaling were unaffected by semaglutide.
Why It Matters
This research clarifies that semaglutide's weight-loss benefits are unlikely due to impaired taste, addressing a long-standing clinical question. Patients using semaglutide can be reassured that their taste perception is not being negatively impacted, which is important for quality of life and adherence. The finding that semaglutide increased licking and trial initiation for sucrose suggests it might enhance motivational aspects of feeding rather than altering taste itself, pointing to novel GLP-1R-mediated mechanisms beyond simple satiety. This could inform future strategies for obesity management, focusing on motivational pathways rather than taste modulation. While a mouse study, it provides strong preclinical evidence against taste impairment.
semaglutide
obesity
taste
ingestive-behavior
glp-1-agonist
preclinical-animal